OLANZAPINE Drug Patent Profile

When do Olanzapine patents expire, and when can generic versions of Olanzapine launch?

Olanzapine is a drug marketed by Am Regent, Aspiro, Eugia Pharma, Qilu, Sandoz Inc, UBI, Ajanta Pharma Ltd, Apotex Inc, Aurobindo Pharma Ltd, Barr Labs Inc, Chartwell Molecular, Dr Reddys Labs Ltd, Hec Pharm, Hisun Pharm Hangzhou, Jubilant Generics, Macleods Pharms Ltd, Orbion Pharms, Pharmobedient, Strides Pharma Intl, Sun Pharm Inds, Torrent, Zydus Pharms, Alkem Labs Ltd, Cadila Pharms Ltd, Hikma, Indoco, Ivax Pharms Inc, Jiangsu Hansoh Pharm, Natco Pharma, Sunshine, Teva Pharms, Torrent Pharms Ltd, Epic Pharma Llc, and Ph Health. and is included in forty-eight NDAs.

The generic ingredient in OLANZAPINE is fluoxetine hydrochloride; olanzapine. There are twenty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride; olanzapine profile page.

Summary for OLANZAPINE

US Patents:	0
Applicants:	34
NDAs:	48
Finished Product Suppliers / Packagers:	43
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	537
Patent Applications:	4,365
Drug Prices:	Drug price information for OLANZAPINE
Drug Sales Revenues:	Drug sales revenues for OLANZAPINE
DailyMed Link:	OLANZAPINE at DailyMed

See drug prices for OLANZAPINE

See drug sales revenues for OLANZAPINE

Recent Clinical Trials for OLANZAPINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	PHASE4
University Hospital, Strasbourg, France	PHASE2
Roswell Park Cancer Institute	PHASE2

See all OLANZAPINE clinical trials

Pharmacology for OLANZAPINE

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for OLANZAPINE

N05AH	Diazepines, oxazepines, thiazepines and oxepines
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for OLANZAPINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ajanta Pharma Ltd	OLANZAPINE	olanzapine	TABLET;ORAL	206711-002	Aug 30, 2016		DISCN	No	No
Chartwell Molecular	OLANZAPINE	olanzapine	TABLET;ORAL	203333-001	Mar 15, 2016	AB	RX	No	No
Jubilant Generics	OLANZAPINE	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	200221-003	Sep 12, 2012	AB	RX	No	No
Hec Pharm	OLANZAPINE	olanzapine	TABLET, ORALLY DISINTEGRATING;ORAL	208146-002	Jul 2, 2018	AB	RX	No	No
Sunshine	OLANZAPINE	olanzapine	TABLET;ORAL	206238-004	Nov 19, 2018		DISCN	No	No
Qilu	OLANZAPINE	olanzapine	TABLET;ORAL	204319-006	Jan 27, 2016	AB	RX	No	No
Apotex Inc	OLANZAPINE	olanzapine	TABLET;ORAL	090798-004	Apr 23, 2012	AB	RX	No	No

EU/EMA Drug Approvals for OLANZAPINE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Zyprexa Velotab	olanzapine	EMEA/H/C/000287AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	no	no	no	2000-02-03
Eli Lilly Nederland B.V.	Zypadhera	olanzapine	EMEA/H/C/000890Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.	Authorised	no	no	no	2008-11-19
Eli Lilly Nederland B.V.	Zyprexa	olanzapine	EMEA/H/C/000115Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.	Authorised	no	no	no	1996-09-27
Krka	Zalasta	olanzapine	EMEA/H/C/000792Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-09-27
Mylan Pharmaceuticals Limited	Olanzapine Mylan	olanzapine	EMEA/H/C/000961AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2008-10-06
Teva B.V.	Olanzapine Teva	olanzapine	EMEA/H/C/000810AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2007-12-12
Apotex Europe BV	Olanzapine Apotex	olanzapine	EMEA/H/C/001178Olanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.	Authorised	yes	no	no	2010-06-10

Market Dynamics and Financial Trajectory for Olanzapine

Last updated: November 20, 2025

Introduction

Olanzapine, a second-generation atypical antipsychotic, revolutionized treatment paradigms for schizophrenia, bipolar disorder, and other psychiatric conditions upon its approval. Owned predominantly by Eli Lilly and Company, olanzapine's market footprint continues to evolve amid competitive pressures, patent landscapes, and emerging therapeutic alternatives. This comprehensive analysis evaluates the fundamental market dynamics, financial trajectories, and strategic outlooks shaping olanzapine’s future within the global pharmaceutical landscape.

Pharmacological Profile and Therapeutic Indications

Olanzapine (chemical name: 4-methyl-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,f]azepine) exerts its antipsychotic effects via antagonism of dopamine D2 and serotonin 5-HT2A receptors. Its dual receptor blockade underpins efficacy in managing symptoms of schizophrenia and bipolar disorder, with additional off-label uses extending into agitation and refractory depression management.

The drug's favorable efficacy profile, coupled with a relatively tolerable side effect spectrum—including metabolic disturbances such as weight gain and hyperglycemia—has cemented its position as a first-line agent, especially in severe psychiatric cases. Its prolonged-release formulations and patient-friendly administration routes have also contributed to sustained adherence rates.

Market Landscape and Competitive Environment

Global Market Size and Growth Trends

The global antipsychotic market, valued at approximately $14 billion in 2022, demonstrates a compound annual growth rate (CAGR) of around 5% over the past five years, driven by increasing prevalence of schizophrenia (~20 million affected globally) and bipolar disorder (~60 million globally) [1]. Olanzapine commands a significant share within this space, with sales peaking at over $4.7 billion in 2016 before recent declines.

Patent Expiry and Generic Competition

Eli Lilly’s primary patent protections for olanzapine expired in the US in 2011, with subsequent patent expirations in key markets affecting exclusivity. The rapid entry of generic manufacturers post-patent cliffs led to sharp price erosion—up to 60% in some regions—and reduced Lilly’s market share.

Generic competition remains fierce, with multiple formulations vying for prescriber preference. Notably, branded formulations like Zyprexa (Lilly) have seen their revenues diminish, prompting pharma strategies around marketing, new formulations, and licensing.

Emerging Therapeutics and Competitive Challenges

The pharmaceutical environment includes several novel agents. Atypical antipsychotics such as risperidone, quetiapine, and aripiprazole offer comparable efficacy profiles with varying side effect profiles. Additionally, recent approvals of long-acting injectables (LAIs) and pharmacogenomic-guided therapies threaten traditional olanzapine use cases.

Moreover, mood stabilizers and psycho-social interventions diversify treatment options, challenging olanzapine’s dominance, particularly given its metabolic risk profile, which has led clinicians to consider alternatives.

Market Dynamics Influencing Olanzapine’s Financial Trajectory

1. Patent and Regulatory Factors

Patent expirations, notably in major markets, have driven generic penetration. While initial off-patent formulations led to volume-driven revenues, the intense price competition substantially constrains profitability. Eli Lilly’s strategic pivot toward new formulations, such as Zyprexa Relprevv (a long-acting injectable), aims to recapture premium pricing and address adherence issues.

Regulatory efforts to mitigate off-label use and ensure safety—through REMS (Risk Evaluation and Mitigation Strategies)—further impact distribution dynamics. The FDA’s continuing surveillance of metabolic side effects has led Lilly to promote newer agents with improved safety profiles.

2. Pricing and Reimbursement Trends

Healthcare payers worldwide push toward cost containment. Reimbursement policies favor generic prescriptions and evidence-supported therapies, compress margins for branded olanzapine. Managed care organizations increasingly favor agents with fewer metabolic side effects, such as aripiprazole, unless prescriber preference or patient history justifies olanzapine use.

3. Clinical Practice Shifts

Physicians weigh efficacy against metabolic risks. The metabolic profile of olanzapine incites caution, particularly in populations with comorbidities like diabetes. As a result, utilization is shifting toward agents with more favorable profiles, impacting sales.

4. Innovation and Lifecycle Management

To sustain revenue, Eli Lilly has invested in developing extended-release formulations and combination therapies. Examples include Zyprexa Relprevv, designed to improve adherence. Success of these innovations hinges on market acceptance amid competing injectable antipsychotics.

5. Geographic Market Variations

Emerging markets have shown increasing antipsychotic demand, often characterized by a preferential tilt toward affordable generics. While growth exists in these regions, price sensitivity constrains margins. Conversely, developed markets favor branded formulations where premium pricing can be maintained, particularly with newer formulations.

Financial Trajectory and Revenue Outlook

Historically, olanzapine generated peak revenues exceeding $4.7 billion worldwide. Post-patent expiry, revenues declined sharply, with Lilly reporting revenues in 2022 of approximately $1.2 billion from olanzapine-related products, reflecting sustained but diminished market share.

Future revenues are projected to decline gradually, influenced by generics' continued penetration and clinical practice shifts. However, strategic investments in reformulations and formulations designed for better safety profiles may offset some decline. Analysts expect a compound annual decrease of about 4-6% over the next five years, contingent on regulatory outcomes and product innovation success.

Strategic Outlook and Market Opportunities

1. Focus on Extended-Release and Depot Formulations

Innovative long-acting injectables, with enhanced safety and adherence benefits, could sustain or even grow segments of olanzapine’s market share. These formulations command premiums and cater to chronic management needs.

2. Combination Therapies and Digital Health Integration

Combining olanzapine with adjunct agents or integrating digital adherence platforms can add value and differentiate offerings in an increasingly crowded space.

3. Geographical Expansion and Tiered Pricing

Expanding into emerging markets with tailored, affordable formulations offers revenue opportunities, albeit with lower margins.

4. Emphasis on Safety Profiling and Personalized Medicine

Pharmacogenomic approaches can optimize patient outcomes, reducing side effects and improving treatment adherence, maintaining olanzapine’s relevance against competitors.

Key Takeaways

• Market decline due to patent expirations: Generics have significantly eroded olanzapine’s profitability, with revenues declining by approximately 50% since 2016.

• Innovation as a sustaining strategy: Eli Lilly’s focus on long-acting, safer formulations aims to carve niche markets and support premium pricing.

• Intensified competition from alternative agents: Newer atypical antipsychotics with better side-effect profiles are influencing prescriber preferences.

• Geographic diversification is vital: Emerging markets present growth avenues, though price sensitivity limits profitability.

• Regulatory and safety considerations: Ongoing safety concerns regarding metabolic side effects necessitate strategic positioning and innovation.

Conclusion

Olanzapine’s trajectory exemplifies the challenges and opportunities in the psychiatric pharmacotherapy market. While patent expirations and safety concerns have suppressed revenue streams, strategic innovation and diversified market approaches sustain its relevance. Market forces favor a transition from volume-based sales to value-added formulations and personalized treatment modalities. Stakeholders must navigate patent landscapes, clinical trends, and regulatory frameworks to optimize long-term revenues.

FAQs

1. How has patent expiration affected olanzapine’s market share?

Patent expiration in key markets initiated widespread generic entry, leading to a sharp decline in olanzapine revenues and market share for Eli Lilly, with branded sales diminishing by over 50% since 2011. Generics have captured the majority of prescriptions, intensifying price competition.

2. What are the key safety concerns associated with olanzapine?

Metabolic side effects, including weight gain, hyperglycemia, and dyslipidemia, are prominent concerns. These risks have prompted prescriber caution and influenced the shift toward newer agents with improved safety profiles.

3. What strategic initiatives is Eli Lilly pursuing to sustain olanzapine’s market relevance?

Eli Lilly invests in developing long-acting injectable formulations like Zyprexa Relprevv, focusing on enhancing adherence and safety. Additionally, efforts include combination therapies, digital health integration, and geographic expansion into emerging markets.

4. Are there promising pipeline therapies that could replace olanzapine?

While newer atypical antipsychotics like brexpiprazole and cariprazine, along with dopamine partial agonists, offer alternative treatment options, no direct replacements have rendered olanzapine obsolete. Their safety profiles and efficacy influence their adoption relative to olanzapine.

5. How do reimbursement policies influence olanzapine’s sales?

Cost containment measures prioritize generic, cost-effective options, pressure pricing, and restrict reimbursement for branded formulations. This environment favors generics and diminishes margins for branded olanzapine products.

References

[1] IQVIA. "Global Psychiatry Drugs Market Analysis," 2022.